{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '12 months later via phone or email by research staff to enquire if any treatment for TED', 'has been received since last study contact. If yes, subject will be questioned regarding type', 'of treatment and outcome/response. and will be discharged from the study following', 'completion of the EOT assessments 3 weeks after the last infusion.', 'An overview of the study design is presented in the schematic below, and details of study', 'activities are provided in Section 2.1, Schedule of Assessments.', 'Subjects who were proptosis non-responders in Study HZNP-TEP-301', 'Teprotumumab Open-Label Treatment Period', 'Follow-Up Period', 'Follow-Up Contact4', '24 Weeks\u00b2', '24 Weeks3', '48 Weeks', 'Clinic Visits', '*', 'Day 15,6', 'W1', 'W36', 'W4', 'W6', 'W9', 'W12', 'W15', 'W18', 'W21', 'W247', 'W28', 'W36', 'W488', 'W72', 'W96', 'Baseline', 'M1', 'M3', 'M6', 'M7', 'M9', 'M12', 'M18', 'M24', 'Study Week/Month', 'Subjects who relapsed in Study HZNP-TEP-301', 'Teprotumumab Open-Label Treatment Period\u00b9', 'Follow-Up Contact4', '24 Weeks\u00b2', '48 Weeks', 'Clinic Visits', 'Day 15,6', 'W1', 'W36', 'W4', 'W6', 'W9', 'W12', 'W15', 'W18', 'W21', 'W247', 'W48', 'W72', 'Baseline', 'M1', 'M3', 'M6', 'M12', 'M18', 'Study Week/Month', '*', 'Infusion of study drug. EOS-End of Study; EOT=Endof Treatment; M=Month; W=Week.', '1. Teprotumumab 20 mg/kg (10 mg/kg on Day 1 followed by 20 mg/kg q3W for the remaining 7 infusions). The number of infusions will be', \"individualized for each subject and will be basedon the Investigator's clinical judgment\", '2.', 'Visit windows are 1 day for Weeks 1 and 4, 3 days for Weeks 3, 6, 9, 12, 15, 18, and 21, and 7 days for Week 24 EOT.', '3.', 'Visit windows of 7 days.', '4. Proptosis non-responders from Study HZNP-TEP-301 who complete the Month 12 Visit and subjects who relapsed during the', 'Follow-Up Period of HZNP-TEP-301 and complete the Week 24 Visit.', '5.', 'Visit must occur within 14 days after the final visit of HZNP-TEP-301.', '6.', 'Subjects will be contacted by phone/email the day following the first and second infusions for safety and tolerability assessments;', 'phone/email contacts will also occur the day after any clinic visit where a subject experiences an infusion-related AE.', '7.', 'When the Investigator deems dosing is complete, or ilf a subject wishes to discontinue dosing, the subject will return to the clinic and', 'undergo the scheduled Week 24 EOT assessments.', '8.', 'If a subject participates in the Follow-Up Period and prematurely discontinues prior to Month 12, he/she will return to the clinic and', 'undergo the Month 12EOS assessments prior to study discharge.', 'Inclusion Criteria:', '8.', 'Women of childbearing potential must have a negative urine pregnancy test at', 'Baseline/Day 1. Subjects who are sexually active with a non-vasectomized male', 'partner must and agree to use 2 reliable forms of contraception during the trial and', 'continue for 180 days after the last dose of study drug. One of the 2 forms of', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 8 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'contraception is recommended to be hormonal, such as an oral contraceptive. Hormonal', 'contraception must be in use for at least one full cycle prior to Baseline. Highly effective', 'contraceptive methods (with a failure rate less than 1% per year), when used consistently', 'and correctly, includes implants, injectables, combined oral contraceptives, some', 'intrauterine devices (IUDs), sexual abstinence or vasectomized partner.', '9.', 'Male subjects must be surgically sterile or, if sexually active with a female partner of', 'childbearing potential, must agree to use a barrier contraceptive method from Baseline', 'through 180 days after the last dose of study drug.', 'Exclusion Criteria:', '1.', 'Subjects will be ineligible if, in the opinion of the Investigator, they are unlikely to', 'comply with the study protocol or have a concomitant disease or condition that could', 'interfere with the conduct of the study or potentially put the subject at unacceptable risk.', 'The exclusion criteria (except those related to screening) of protocol HZNP-TEP-301 also', 'apply to this open-label extension study.', 'Dose Regimen/Route of Administration:', 'All study drug dosing will be performed at the clinic under the supervision of clinic staff.', 'Subjects will receive up to-8 infusions of teprotumumab (10 mg/kg on Day 1 followed by', '20 mg/kg q3W for the remaining 7 infusions) in an open-label fashion.; the number of infusions', 'will be determined by the Investigator s clinical judgment.', 'The infusion rate may be reduced and the dose may be interrupted or held based on tolerability', '(see Section 9.4.6.3.2 for details). The first and second infusions will be administered over', 'approximately 90 minutes (but not less than 80 minutes). Subsequent infusions will be', 'administered over approximately 60 minutes (but not less than 50 minutes), period providing', 'there are no significant infusion-associated events.', 'Duration of Treatment and Follow-up', 'The maximum duration of the Treatment Period is 24 weeks (6 months), during which up to', '8 infusions of teprotumumab will be administered.', 'Subjects who complete the study (Month 12 Visit for proptosis non-responders in', 'Study HZNP-TEP-301 and Week 24 Visit for subjects who relapsed during the Follow-up', 'Period in Study HZNP-TEP-301) will be contacted 6 and 12 months after the last visit via', 'phone or email by research staff to enquire if any treatment for TED has been received', 'since last study contact.', 'Criteria for Evaluation:', 'Efficacy will be assessed by proptosis (measured as exophthalmos evaluation of the Clinical', 'Measures of Severity using a Hertel instrument provided by the Sponsor for consistency in', 'measurement), CAS (7-item scale), diplopia (measured as part of the Clinical Measures of', 'Severity) and Clinical Measures of Severity (including motility restriction assessments).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 9 of 118']\n\n###\n\n", "completion": "END"}